FPR2 agonist 3 - Moligand™, 10 mM in DMSO , CAS No.2829263-19-4

CAS: 2829263-19-4 Cat. No.: F1498079 Formula: C₂₅H₂₀F₂N₄O₂ Molecular Weight: 446.45

GRADE & PURITY Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

FPR2 agonist 3 (compound CMC23) can limit the lactate dehydrogenase release in LPS -stimulated cultures and decrease the levels of pro-inflammatory IL-1β and IL-6 . FPR2 agonist 3decrease the level of phosphor-STAT3 via the STAT3/SOCS3 signaling pathway.

Specifications

Specifications & Purity

Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

AGONIST

Names and Identifiers

Molecular Weight

446.45

Application Protocols

No item-specific, tested application protocols are provided for this product. The following are general starting points for FPR2 agonist evaluation and must be optimized by the end user.

Example starting protocols (general):

• Calcium flux (FPR2-expressing cells):
  • Load cells with Fluo‑4/AM in HBSS (with Ca2+/Mg2+) + 20 mM HEPES, 0.02–0.1% BSA; wash and equilibrate; add ligand by rapid injection keeping final DMSO ≤0.1%.
• β‑arrestin recruitment:
  • Use a commercial GPCR β‑arrestin assay platform; seed cells per vendor guidance; treat with a 10‑point dilution series; read luminescence/fluorescence as specified.
• Chemotaxis (primary neutrophils/monocytes):
  • Prepare Boyden chamber with ligand gradient; incubate 30–120 min; quantify migrated cells; include vehicle and positive control ligands.

Controls and quality:

• Include a known FPR2 agonist control, vehicle control, and non‑transfected cells as negative controls.
• Keep constant vehicle concentration across dilutions; verify absence of precipitation visually or by light scattering.

Note: These protocols are generic and not validated for this specific item. Refer to your institutional SOPs and adapt conditions as needed.

Biological Roles

Context for FPR2 biology (general background, not item-specific):

• Receptor: FPR2 (formyl peptide receptor 2; also ALX/FPR2) is a class A GPCR primarily coupling to Gi/o proteins. It is expressed in neutrophils, monocytes/macrophages, dendritic cells, and various non‑immune tissues.
• Endogenous ligands: Specialized pro‑resolving mediators (SPMs) such as lipoxin A4 and resolvins; annexin A1 peptides; selected host‑ and microbe‑derived peptides.
• Signaling: Activation typically suppresses adenylyl cyclase (↓cAMP), and triggers PLCβ/Ca2+ flux, PI3K–Akt, ERK/MAPK, and small GTPase pathways, modulating chemotaxis, phagocytosis, and effector functions.
• Functional outcomes: FPR2 is implicated in the resolution phase of inflammation, promoting pro‑resolving, anti‑exudative programs and efferocytosis in myeloid cells. Effects are context‑ and ligand‑biased, with potential for differential signaling vs FPR1.
• Assay considerations: Species differences exist among human/mouse/rat FPR2 orthologs; potency/efficacy and bias can shift with receptor expression level and membrane context.

Relevance of an FPR2 agonist standard in research:

• Tool compound roles: Benchmark agonists enable dissecting FPR2 signaling bias, mapping downstream pathways, and establishing structure–activity relationships.
• Application domains: Innate immunity, inflammation resolution biology, and GPCR biased agonism studies in cell lines or primary myeloid cells.

Note: No pharmacokinetic, in vivo, or clinical attributes are provided or implied for this item. Use strictly for laboratory research.

Buffer Applications

This molecule is a bioactive ligand rather than a buffering agent. However, buffer selection is critical for reproducible FPR2 agonist assays.

Assay buffer considerations (general, not item-specific):

• Calcium flux and chemotaxis:
  • HBSS (with Ca2+/Mg2+) + 20 mM HEPES, pH 7.3–7.4, 0.1% fatty‑acid‑free BSA to reduce nonspecific adsorption.
• β‑arrestin and cAMP assays:
  • CO2‑independent HBSS/DPBS + 20 mM HEPES for room‑temperature assays, or phenol‑red‑free complete media for 37°C live‑cell readouts.
• Final vehicle percentage:
  • Maintain DMSO or ethanol at ≤0.1–0.5% v/v across all wells (including controls) to limit solvent effects.
• Adsorption mitigation:
  • Use low‑bind plastics or pre‑coat with 0.1% BSA; verify recovery by LC–MS if potency drifts with plate type.
• Filtration and sterility:
  • Filter buffers (0.22 µm) for cell‑based assays; equilibrate to assay temperature to avoid pH drift.

Not provided for this item:

• Buffer pKa or buffering capacity (not applicable).
• Any item‑specific compatibility notes. Consult the CoA/Spec Sheet and validate empirically in your assay format.

Green Alternatives

Green chemistry considerations for handling bioactive small molecules focus on solvent minimization, safer carriers, and waste reduction rather than on synthetic substitutions.

Strategies (general, not item-specific):

• Prefer water-rich assay media: Use HBSS/DPBS with ≤0.1–0.5% DMSO to limit organic solvent burden.
• Reduce DMSO mass: Prepare higher‑concentration master stocks to minimize delivered DMSO per well; employ acoustic dispensing where available.
• Alternative vehicles: Evaluate ethanol or biobased PEG derivatives at low percentages; consider cyclodextrin complexes to enhance aqueous delivery, recognizing potential impacts on free concentration.
• Miniaturize assays: Transition from 96‑ to 384/1536‑well formats to cut solvent volumes and waste.
• Closed‑loop solvent management: Collect segregated DMSO/organic waste for recovery per institutional green chemistry programs.

Illustrative comparison (general):

• DMSO: High solvency, low volatility, readily recyclable; biological effects above ~0.5%.
• Ethanol (bio‑ethanol): Renewable source; higher volatility; can perturb membranes at modest %.
• CPME/2‑MeTHF: Greener options for synthetic workups, but rarely needed for biochemical assays.

Trade‑offs: Cyclodextrin and PEG vehicles can introduce assay artifacts or alter apparent potency by changing free fraction; validate with binding/functional controls. No item‑specific greener substitute is designated; adapt to your assay and EHS policies.

Pharmaceutical Uses

This product is supplied strictly for research use; it is not an approved drug substance, excipient, or GMP material. No pharmacopeial monograph or clinical formulation information is provided for this item.

Research formulation context (general, not item-specific):

• Preclinical dosing vehicles often used for lipophilic small molecules include combinations such as 5–20% PEG400, 0–5% DMSO or ethanol, 0.5–2% Tween 80 or Cremophor EL, and saline or citrate buffer as balance. Selection should be guided by institutional IACUC policies and compound solubility/stability.
• For parenteral research studies, sterile filtration (0.22 µm) and endotoxin control are critical; verify compatibility beforehand to prevent precipitation.
• For oral gavage in animal research, suspensions in 0.5% methylcellulose + 0.2% Tween 80 are commonly used for poorly soluble compounds; confirm dose uniformity.

Cautions:

• Do not use in humans or for diagnostic/therapeutic purposes.
• No statements are made regarding safety, efficacy, or dosage. Investigators are responsible for all regulatory and ethical compliance in preclinical work.

Physical Properties

Item-specific physicochemical data have not been provided for this catalog entry.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Melting/boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
• pKa(s): Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not applicable/unknown for solids; Not specified for this item; refer to CoA/Spec Sheet.
• Solubility profile: Not specified for this item; refer to CoA/Spec Sheet.

General, literature-style guidance for small-molecule screening ligands (not item-specific):

• Initial dissolution: Prepare a concentrated stock (e.g., 10–50 mM) in anhydrous DMSO; vortex and sonicate briefly if needed. Filter (0.22 µm PTFE) for assay-critical work.
• Aqueous working solutions: Dilute DMSO stocks into assay buffers (e.g., HBSS or PBS ± Ca/Mg) keeping final DMSO ≤0.1–0.5% v/v, per cell/tissue tolerance.
• Solubility troubleshooting: Explore co-solvents (ethanol, DMF) or vehicles (0.5–2% Tween 80, 2–10% PEG400, 2‑hydroxypropyl‑β‑cyclodextrin) consistent with your biology. Confirm absence of colloids by light scattering when feasible.
• Stability checks: Verify integrity over time by LC–MS/UPLC (freeze–thaw, short-term bench exposure, and assay temperature holds). Protect from light if chromophores are suspected.

Quality & Grades

• Grade/Purity: Moligand™

What Moligand™ signifies (general description):

• Intended use: Discovery-grade bioactive small molecules optimized for screening, target validation, and SAR exploration. Not for human or veterinary use.
• Typical QC elements for this class: Identity by LC–MS and/or NMR; chromatographic purity by HPLC/UPLC; water/solvent content by KF/GC as applicable; salt form verification when relevant. Note: Item‑specific acceptance limits are not provided here—refer to the CoA/Spec Sheet.
• UV/fluorescence behavior: Not specified for this item; confirm if low‑UV (HPLC) or fluorescent interference is a concern in your assay.
• Counter-ions/solvates/polymorph: Not specified for this item. These can affect solubility and potency readouts; verify on receipt via CoA.

What is specific to this item:

• Product identity: FPR2 agonist 3 (CAS 2829263-19-4)
• Item-specific data such as exact purity %, residual solvents, stabilizers, or metal limits: Not specified for this item; refer to CoA/Spec Sheet.

Practical guidance:

• On receipt, perform a quick LC–MS/HPLC check to benchmark purity/identity against the CoA.
• For screening plates, aliquot into inert, low‑bind tubes/plates under dry conditions to avoid hygroscopic uptake and freeze–thaw cycles.
• If orthogonal biophysical assays are used (SPR, MST, DSF), ensure buffer blanks to control for aggregation or surfactant sensitivity.

Reaction & Applications

This product is supplied as a bioactive small-molecule ligand for receptor pharmacology rather than as a synthetic reagent. As such, classical synthetic reaction applications (e.g., cross‑coupling, oxidations, Grignard) are not typically applicable.

Biological/assay applications relevant to FPR2 agonists (general, not item-specific):

• Receptor activation readouts:
  • Calcium flux assays in FPR2‑expressing cells (e.g., Fluo‑4/AM dyes) under Gi‑coupled GPCR conditions.
  • β‑arrestin recruitment (enzyme fragment complementation, BRET, or luminescent platforms).
  • cAMP inhibition assays (Gi‑linked) using luminescent or HTRF kits.
• Functional cell responses:
  • Neutrophil/monocyte chemotaxis in Boyden chambers or microfluidic gradients.
  • Phagocytosis, ROS burst, and degranulation assays in primary myeloid cells.
• Systems biology:
  • RT‑qPCR or RNA‑seq of pro‑resolving gene signatures following ligand exposure.

Practical considerations:

• Confirm FPR2 expression (qPCR, Western blot, flow) in your system; include antagonist or CRISPR‑KO controls to ensure on‑target responses.
• Titrate the ligand across ≥8–12 half‑log dilutions; keep constant vehicle concentration.
• Include orthogonal agonists (e.g., known FPR2 reference ligands) to benchmark assay windows.

For any chemistry transformations using this molecule as a substrate or handle, no information is provided; users should treat it as not intended for synthetic conversion.

Reaction Conditions

Classical organic reaction conditions do not generally apply to this product, which is supplied as a ready‑to‑use bioactive ligand rather than a reagent for chemical synthesis.

General guidance for biological assay conditions (not item-specific):

• Concentration ranges: Start with a broad 8–12 point half‑log dilution series (e.g., 0.1 nM to 30 µM) to map potency and efficacy; avoid exceeding solubility limits.
• Temperature: Maintain physiological temperatures (25–37°C) as required by the assay; equilibrate buffers to prevent CO2‑related pH drift.
• Incubation times: GPCR functional readouts often occur within seconds to minutes (Ca2+ flux), while transcriptional responses may require 1–6 h.
• Controls: Include vehicle controls, a known FPR2 agonist as positive control, and pathway blockers (e.g., pertussis toxin for Gi coupling) as mechanistic controls.
• Data analysis: Fit concentration–response curves with a 4‑parameter logistic model; report EC50 and Emax with confidence intervals.

Item-specific catalysts, temperatures, or yields are not applicable and are not provided.

Safety & Handling

Hazard classification for this specific item is not provided in the product data. Treat as a laboratory chemical of unknown hazards and consult the SDS for authoritative guidance.

• GHS classification, pictograms, H‑statements: Not specified for this item; refer to SDS.
• Signal word: Not specified for this item; refer to SDS.

General laboratory precautions (non‑item‑specific):

• PPE: Lab coat, safety glasses, and suitable gloves (e.g., nitrile). Upgrade to splash goggles/face shield for large-scale handling.
• Engineering controls: Work in a chemical fume hood or suitable ventilated enclosure. Use a biosafety cabinet only for sterile operations after chemical handling is complete.
• Avoid exposure: Many bioactive small molecules can be potent at sub‑micromolar levels. Avoid inhalation and skin contact; minimize DMSO-mediated dermal absorption by wearing gloves and promptly cleaning spills.
• Incompatibilities: Unknown for this item; as general practice, avoid strong oxidizers/reducers, strong acids/bases until compatibility is confirmed.
• First aid (overview): If on skin/eyes, rinse with water for ≥15 minutes and remove contaminated clothing. If inhaled, move to fresh air. If ingested, rinse mouth and seek medical attention. Always follow your institution’s EHS protocols and the SDS.
• Disposal: Collect as organic hazardous waste; segregate halogenated vs non‑halogenated per local regulations.
• Special risks: None specified. If the compound is an ether/aldehyde/thiol or light‑sensitive chromophore, additional peroxidation or photolysis precautions may apply—verify via CoA/SDS.

Solvent Selection

Because the precise structure is not provided, solvent choice should follow a robust triage approach used for diverse small molecules.

• Primary stock solvent (general best practice):
  • DMSO (anhydrous) for 10–50 mM master stocks; miscible with water and many buffers; broadly compatible with cell‑based GPCR assays when final v/v ≤0.1–0.5%.
• Alternative co‑solvents (case‑by‑case):
  • Ethanol or DMF for sparingly soluble compounds; ensure biological compatibility at ≤0.1–0.5% in final assays.
  • PEG400 (2–20%) or 2‑hydroxypropyl‑β‑cyclodextrin (5–20% w/v) for in vivo research vehicles or difficult solubilization scenarios.
• Aqueous buffers for GPCR assays:
  • HBSS or DPBS, optionally with Ca2+/Mg2+; 10–20 mM HEPES for pH stability at 25–37°C.
  • Add 0.1% fatty‑acid‑free BSA if adsorption to plastics is suspected.

Comparison snapshot (general):

• DMSO: Highest solvating power; may affect membrane dynamics at >0.5% v/v.
• Ethanol: Volatile, rapid mixing; stronger effects on some cells above 0.3% v/v.
• PEG400: Good carrier for hydrophobes; viscous, may alter diffusion/assay kinetics.
• Cyclodextrins: Enhance aqueous solubility; can sequester lipophilic ligands—control carefully.

Note: No item-specific solubility, pKa, or logP data are available; verify empirically and consult the CoA/Spec Sheet for any provided solvent guidance.

Storage & Reconstitution

Storage conditions and shipping for this item:

• Storage: Store at −80°C (per product data).
• Shipped in: Dry ice packs + Cold packs (per product data).

General handling and reconstitution guidance (not item-specific; defer to CoA if provided):

• Upon receipt: Allow shipping containers to equilibrate to room temperature before opening to minimize condensation; promptly transfer vials to −80°C.
• Aliquoting: If supplied as a solid, work quickly under dry conditions; if supplied as a DMSO solution, prepare single‑use aliquots to avoid freeze–thaw cycles.
• Reconstitution: Dissolve in anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM). Vortex/sonicate briefly. Record exact concentration by weight-in or by UV only if extinction coefficient is known.
• Working solutions: Dilute into assay buffer or media immediately before use; maintain final DMSO ≤0.1–0.5% v/v as tolerated by your system.
• Stability: Protect from repeated freeze–thaw and from light if chromophores are suspected. For long‑term storage of DMSO stocks, keep tightly sealed under inert gas at −80°C.
• Documentation: Retain lot CoA and any stability notes with your inventory record; relabel aliquots with concentration, solvent, date, and operator initials.

Item‑specific stabilizers, hydrate/solvate status, and exact reconstitution solvents: Not specified for this item; refer to CoA/Spec Sheet.

Structure & Identity

Brief overview: FPR2 agonist 3 is a small‑molecule research ligand supplied under Aladdin’s Moligand™ grade for GPCR target exploration, named for its putative activity at the formyl peptide receptor 2 (FPR2/ALX). Item‑specific structural descriptors are not provided for this catalog entry.

• SKU: F1498079
• Product name: FPR2 agonist 3
• CAS: 2829263-19-4
• Category: Small molecules and compound libraries (screening ligand)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural features: Not specified for this item; refer to CoA/Spec Sheet.

2D structural description (general): Because no structure is supplied, a text description of rings/functional groups or stereochemistry cannot be provided for this item. If structure is needed for docking/virtual screening or analytical method development, request the CoA/Spec Sheet from Aladdin or use the CAS to query internal databases.

Identity confirmation (general guidance):

• Recommended orthogonal ID methods: LC–MS (ESI±), 1H/13C NMR, and HRMS where available.
• Purity/identity acceptance criteria should be set by your lab’s screening SOPs; defer to CoA for item‑specific thresholds.

Synthetic Utility

As supplied, FPR2 agonist 3 is intended as a bioactive tool compound, not as a synthetic building block. Without a disclosed structure, discussion of functional group reactivity, protecting group strategies, or named transformations would be speculative.

Practical guidance (general):

• If derivatization is desired for probe development (e.g., biotinylation, fluorophore conjugation, photoaffinity tagging), request structural information and IP permissions. Perform SAR to confirm retained agonism after modification.
• For analytical tagging, consider reversible or noncovalent approaches (e.g., cyclodextrin complexation) if structure is unknown.
• If used as a reference standard, develop stability‑indicating HPLC/UPLC methods with at least two orthogonal detectors (UV and MS) to monitor degradation pathways under stress (acid/base, oxidative, light, thermal).

Summary: No item-specific synthetic transformations can be recommended; treat this material as a finalized ligand for biological assays rather than a substrate for chemical synthesis.

Target Specificity

Only product-derived information is provided here.

• Listed target/context from product name: FPR2 (formyl peptide receptor 2) agonist
• Species reactivity, selectivity vs FPR1/FPR3, EC50/KB, or bias profile: Not specified for this item; refer to CoA/Spec Sheet or primary data packages if available.
• Clone/isotype/epitope: Not applicable (small molecule).

Recommendations:

• Independently confirm target engagement using orthogonal assays (e.g., β‑arrestin and Ca2+ flux) and counter‑screen against FPR1/FPR3 if those receptors are present in your system.
• Verify species activity if using non‑human orthologs.

Frequently Asked Questions

What is Moligand??

Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2829263-19-4, the molecular formula is C25H20F2N4O2, and the molecular weight is 446.45 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.